Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib + TAS-102 in advanced metastatic CRC
NCT05004831Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2022
- Primary completion
- Sep 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fruquintinib in metastatic colorectal cancer (mCRC), sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival up to 2 years. Status: unknown.
02
Drugs
fruquintinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05004831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05004831.